Panic Disorder Clinical Trial
Official title:
Long-term, Open, Naturalistic, Randomized Clinical Trial With Clonazepam and Paroxetine in Panic Disorder With or Without Agoraphobia
The purpose of this study was to determine whether clonazepam and paroxetine are effective in the treatment of panic disorder. Efficacy was evaluated in short-term, long-term and post-treatment.
The current study consisted of three steps. The first step was a naturalistic, prospective,
randomized, open clinical trial with clonazepam and paroxetine. Subjects received either
flexible dose clonazepam (0.5 - 2 mg/day) or paroxetine (10 - 40 mg/day), in monotherapy for
eight weeks. In the second step, those who responded to monotherapy in the short-term study
continued with the same drug and dose. Partial responders or non-responders were invited to
receive combined pharmacological treatment with clonazepam and paroxetine. Patients received
the maximum tolerated doses of clonazepam and paroxetine. The doses were flexible, ranging
from 0.5 to 2 mg/day for clonazepam and from 10 to 40 mg/day of paroxetine. All patients
were treated for 34 months in the second step. Patients who completed the second step and
were in remission were included in the third step. For a period of four months all
medications were tapered off. These patients were followed for 6 years with evaluations once
a year. Those who relapsed were treated on a naturalistic basis, with drugs or
psychotherapy.
This study was conducted in accordance with the ethical principles established by the
Declaration of Helsinki and the Brazilian National Ethics Committee (Conselho Nacional de
Ética em Pesquisa - CONEP) guidelines. The local Ethics Committee approved the study
protocol. Written informed consent was obtained from all patients.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05868135 -
Effects and Cost-effectiveness of e-Meistring - a Guided Internet-delivered Psychological Treatment
|
||
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Completed |
NCT02998502 -
The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens
|
N/A | |
Completed |
NCT01963806 -
ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder
|
N/A | |
Completed |
NCT01955954 -
Using the Canary Breathing System for Panic Disorder Patients
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Completed |
NCT00605813 -
Special Investigation Of Long Term Use Of Sertraline.
|
||
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00353470 -
Comparison of Psychotherapy Programs to Treat Panic Disorder
|
Phase 3 | |
Completed |
NCT00167479 -
A Study of Risperidone Monotherapy in Bipolar Anxiety
|
Phase 4 | |
Completed |
NCT00540098 -
Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder
|
Phase 4 | |
Completed |
NCT03233542 -
The Association Between Physical Sensations and Thinking Styles
|
N/A | |
Recruiting |
NCT05967468 -
Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder
|
N/A | |
Completed |
NCT02811458 -
Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders
|
N/A | |
Active, not recruiting |
NCT05124639 -
Clinical Trial of a Group Self-management Support Program for Anxiety Disorders
|
N/A | |
Completed |
NCT04592536 -
A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects
|
Phase 1 | |
Completed |
NCT00025974 -
Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder
|
N/A | |
Recruiting |
NCT02305537 -
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
|
N/A | |
Terminated |
NCT01680107 -
D-cycloserine Augmented CBT for Panic Disorder
|
Phase 3 |